Enzychem Lifesciences transfers technology for pDNA vaccine ZyCoV-D
Enzychem Lifesciences transfers technology for pDNA vaccine ZyCoV-D
  • Kevin Lee 기자
  • 승인 2021.12.29 11:25
  • 댓글 0
이 기사를 공유합니다

Secures the world's first pDNA vaccine technology

Enzychem Lifesciences announced on Dec. 29 that it has begun a technology transfer process for the pDNA vaccine ZyCoV-D of Zydus Cadila in India.

Recently, it secured detailed technical documents including manufacturing processes, raw and subsidiary materials, clinical and non-clinical data from Zydus.

ZyCoV-D is the world's first DNA-based vaccine that was approved for emergency use by the Indian medicines control bureau (DCGI) in August. Unlike conventional vaccines, which were only available for adults over the age of 18, ZyCoV-D can also be used for children over the age of 12.

In particular, it shows good thermal stability, so it can be stored at 2 to 8°C, and can be stored at 25°C for 3 months, which is advantageous for global supply.

Enzychem Lifesciences is pushing for approval procedures for domestic and foreign vaccine supply, including approval for registration in eight Southeast Asian and South American countries, WHO's emergency use registration (EUL) and emergency use approval (EUA) by the Ministry of Food and Drug Safety.

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.